BDX vs. BSX, DXCM, RMD, SYK, PODD, BAX, WST, HCA, GSK, and HUM
Should you be buying Becton, Dickinson and stock or one of its competitors? The main competitors of Becton, Dickinson and include Boston Scientific (BSX), DexCom (DXCM), ResMed (RMD), Stryker (SYK), Insulet (PODD), Baxter International (BAX), West Pharmaceutical Services (WST), HCA Healthcare (HCA), GSK (GSK), and Humana (HUM). These companies are all part of the "medical" sector.
Becton, Dickinson and vs.
Becton, Dickinson and (NYSE:BDX) and Boston Scientific (NYSE:BSX) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, media sentiment, dividends, community ranking, analyst recommendations, valuation, risk and profitability.
Becton, Dickinson and has a net margin of 8.47% compared to Boston Scientific's net margin of 5.50%. Boston Scientific's return on equity of 14.29% beat Becton, Dickinson and's return on equity.
In the previous week, Boston Scientific had 19 more articles in the media than Becton, Dickinson and. MarketBeat recorded 31 mentions for Boston Scientific and 12 mentions for Becton, Dickinson and. Becton, Dickinson and's average media sentiment score of 0.81 beat Boston Scientific's score of 0.21 indicating that Becton, Dickinson and is being referred to more favorably in the media.
Becton, Dickinson and presently has a consensus target price of $271.89, suggesting a potential upside of 13.35%. Boston Scientific has a consensus target price of $51.50, suggesting a potential upside of 5.77%. Given Becton, Dickinson and's higher probable upside, research analysts plainly believe Becton, Dickinson and is more favorable than Boston Scientific.
Becton, Dickinson and has a beta of 0.53, meaning that its share price is 47% less volatile than the S&P 500. Comparatively, Boston Scientific has a beta of 0.79, meaning that its share price is 21% less volatile than the S&P 500.
Boston Scientific received 368 more outperform votes than Becton, Dickinson and when rated by MarketBeat users. Likewise, 69.96% of users gave Boston Scientific an outperform vote while only 62.42% of users gave Becton, Dickinson and an outperform vote.
Becton, Dickinson and has higher revenue and earnings than Boston Scientific. Becton, Dickinson and is trading at a lower price-to-earnings ratio than Boston Scientific, indicating that it is currently the more affordable of the two stocks.
87.1% of Becton, Dickinson and shares are owned by institutional investors. Comparatively, 90.2% of Boston Scientific shares are owned by institutional investors. 0.3% of Becton, Dickinson and shares are owned by company insiders. Comparatively, 0.7% of Boston Scientific shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Summary
Boston Scientific beats Becton, Dickinson and on 13 of the 19 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding BDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Becton, Dickinson and Competitors List